Roche and Exelis/Ipsen's drug combination shows promise in phase 3 prostate cancer study
26 Jan 2024
Clinical ResultPhase 3ASCOImmunotherapy
Preview
Source: PMLiVE
A combination of Roche’s Tecentriq (atezolizumab) and Exelixis/Ipsen’s Cabometyx (cabozantinib) has shown promising results in patients with metastatic castration-resistant prostate cancer (mCRPC), according to phase 3 data detailed by Exelixis.
The late-stage CONTACT-02 trial has been evaluating the combination compared to a second novel hormonal therapy (NHT) in patients with mCRPC and measurable extra-pelvic soft tissue disease who have progressed on one prior NHT.
Approximately 299,000 new cases of prostate cancer will be diagnosed in the US and over 35,000 people will die from the disease in 2024, according to the American Cancer Society.
Patients diagnosed with mCRPC – when the disease has spread beyond the prostate and does not respond to androgen-suppression therapies – often have a poor prognosis, with an estimated survival of one to two years.
Detailed results presented at this year's American Society of Clinical Oncology Genitourinary Cancers Symposium showed that, at a median follow-up of 14.3 months for the first 400 randomised patients in the intent-to-treat (PFS ITT) population, the hazard ratio was 0.65. The median PFS was 6.3 months for Tecentriq/Cabometyx combination, compared with 4.2 months for second NHT.
Additionally, after a follow-up of 12 months, the ITT population had a median overall survival (OS) of 16.7 months, compared to 14.6 months in the hormone population. Despite this trend towards OS improvement, the data was immature and did not meet the threshold for statistical significance, and the study will continue to the next analysis of OS.
“Patients with mCRPC with prior progression on a novel hormone therapy and who have measurable soft tissue metastasis experience the worst outcomes among advanced prostate cancer patients and have limited treatment options,” said global lead investigator of the trial, Neeraj Agarwal, the University of Utah.
He continued: “CONTACT-02 is the only phase 3 study evaluating a tyrosine kinase inhibitor and an immune checkpoint inhibitorimmune checkpoint inhibitor to show a statistically significant improvement in progression-free survival and a trend for overall survival in these patients. I am encouraged by these results and the potential for [Cabometyx] plus [Tecentriq] to be a widely available treatment option for our patients.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.